All In Biotech

Drug Trial Radar · NCT06996652

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Aug 17, 2026

Primary completion

Aug 1, 2029

Study completion Jan 1, 2030

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Marcus Foundation; National Institute on Aging (NIA); University of Rochester - Center for Health + Technology (CHeT)/Clinical Trials Coordinaton Center (CTCC); The Parkinson Study Group
First posted
May 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study to assess the ability of adalimumab as compared to placebo to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD). The Primary Endpoint will be change from baseline in expression of the Parkinson Disease Related Pattern (PDRP) will be assessed using change in 18-flurodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging.

Conditions

  • REM Sleep Behavior Disorder

Interventions

  • AdalimumabDrug

    40 mg self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years

  • PlaceboDrug

    40 mg matching placebo self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Parkinson Disease Related Pattern (PDRP) expressionTime frame: Baseline and Week 96

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center

    Los Angeles, California · Not yet recruiting

  • University of Colorado Anschutz

    Aurora, Colorado · Recruiting

  • Yale Medicine

    North Haven, Connecticut · Recruiting

  • Parkinson's Disease & Movement Disorders Center of Boca Raton

    Boca Raton, Florida · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Not yet recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Not yet recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Not yet recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas

    Las Vegas, Nevada · Not yet recruiting

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire · Not yet recruiting

  • Weill Medical College of Cornell University

    New York, New York · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Not yet recruiting

  • University of Texas Health Science Center- San Antonio

    San Antonio, Texas · Recruiting

  • Montreal Neurological Institute-Hospital at McGill University

    Montreal, Quebec, Canada · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.